TW202104230A - 用於治療自體免疫疾病之六氫-1H-吡并[1,2-a]吡化合物 - Google Patents

用於治療自體免疫疾病之六氫-1H-吡并[1,2-a]吡化合物 Download PDF

Info

Publication number
TW202104230A
TW202104230A TW109111749A TW109111749A TW202104230A TW 202104230 A TW202104230 A TW 202104230A TW 109111749 A TW109111749 A TW 109111749A TW 109111749 A TW109111749 A TW 109111749A TW 202104230 A TW202104230 A TW 202104230A
Authority
TW
Taiwan
Prior art keywords
methyl
hexahydro
amino
carbonitrile
quinoline
Prior art date
Application number
TW109111749A
Other languages
English (en)
Chinese (zh)
Inventor
劉永福
劉海俠
宏 沈
朱偉
張志森
寇步雨
戴略
張志偉
法比恩 迪
劉亞飛
朱莉諾
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202104230A publication Critical patent/TW202104230A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW109111749A 2019-04-09 2020-04-08 用於治療自體免疫疾病之六氫-1H-吡并[1,2-a]吡化合物 TW202104230A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2019081900 2019-04-09
WOPCT/CN2019/081900 2019-04-09
CN2019121598 2019-11-28
WOPCT/CN2019/121598 2019-11-28
WOPCT/CN2020/078225 2020-03-06
CN2020078225 2020-03-06

Publications (1)

Publication Number Publication Date
TW202104230A true TW202104230A (zh) 2021-02-01

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109111749A TW202104230A (zh) 2019-04-09 2020-04-08 用於治療自體免疫疾病之六氫-1H-吡并[1,2-a]吡化合物

Country Status (19)

Country Link
US (1) US20220340597A1 (cg-RX-API-DMAC10.html)
EP (1) EP3953356B1 (cg-RX-API-DMAC10.html)
JP (1) JP7692838B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210149163A (cg-RX-API-DMAC10.html)
CN (1) CN113710672B (cg-RX-API-DMAC10.html)
AU (1) AU2020272467A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021020297A2 (cg-RX-API-DMAC10.html)
CA (1) CA3135129A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021002621A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021013166A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210513A (cg-RX-API-DMAC10.html)
IL (1) IL286870A (cg-RX-API-DMAC10.html)
MA (1) MA55594A (cg-RX-API-DMAC10.html)
MX (1) MX2021012223A (cg-RX-API-DMAC10.html)
PE (1) PE20212178A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021552533A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202110401WA (cg-RX-API-DMAC10.html)
TW (1) TW202104230A (cg-RX-API-DMAC10.html)
WO (1) WO2020207991A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599652B (zh) * 2019-10-31 2024-07-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
WO2021094301A1 (en) * 2019-11-12 2021-05-20 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
EP4061816A1 (en) 2019-11-19 2022-09-28 F. Hoffmann-La Roche AG Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CN114761406B (zh) 2019-12-03 2024-04-19 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
JP2023533807A (ja) * 2020-07-14 2023-08-04 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2663555T3 (en) * 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
HRP20171981T1 (hr) 2012-09-14 2018-02-09 F. Hoffmann - La Roche Ag Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti
US9643967B2 (en) * 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
JP2021527100A (ja) * 2018-06-13 2021-10-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物
CN112752755A (zh) * 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物

Also Published As

Publication number Publication date
AU2020272467A1 (en) 2021-10-14
WO2020207991A1 (en) 2020-10-15
PH12021552533A1 (en) 2022-06-20
PE20212178A1 (es) 2021-11-09
EP3953356C0 (en) 2023-07-26
EP3953356B1 (en) 2023-07-26
CO2021013166A2 (es) 2021-12-10
SG11202110401WA (en) 2021-10-28
BR112021020297A2 (pt) 2021-12-14
CN113710672A (zh) 2021-11-26
IL286870A (en) 2021-10-31
EP3953356A1 (en) 2022-02-16
JP7692838B2 (ja) 2025-06-16
CN113710672B (zh) 2025-01-03
MA55594A (fr) 2022-02-16
CR20210513A (es) 2021-11-02
MX2021012223A (es) 2021-11-03
CA3135129A1 (en) 2020-10-15
KR20210149163A (ko) 2021-12-08
JP2022527588A (ja) 2022-06-02
CL2021002621A1 (es) 2022-05-13
US20220340597A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
JP6571215B2 (ja) Btk活性阻害剤としてのヘテロアリールピリドン及びアザピリドン化合物
US12006325B2 (en) Substituted furanopyrimidine compounds as PDE1 inhibitors
JP7692838B2 (ja) 自己免疫疾患の治療のためのヘキサヒドロ-1H-ピラジノ[1,2-a]ピラジン化合物
TW202024065A (zh) 用於治療自體免疫疾病之雜環基化合物
US20240366769A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CN114728976B (zh) 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
TW202016111A (zh) 用於治療自體免疫疾病之新穎四氫-1H-吡并[2,1-a]異吲哚基喹啉化合物
EP4303216A1 (en) Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof
TW201831476A (zh) 吡啶并〔3,4-d〕嘧啶衍生物及其藥學上所容許之鹽
EP4051387B1 (en) Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
EP3623369B1 (en) Novel morpholinyl amine compounds for the treatment of autoimmune disease
CN112673007A (zh) 用于治疗自身免疫性疾病的吡唑并吡啶胺化合物
HK40055574B (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
WO2023247590A1 (en) Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors
HK40055574A (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
CA3285578A1 (en) New e3 ubiquitin ligase ligand, protein degradation agent and use thereof
WO2023247595A1 (en) Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors